In the current study, chemotherapy was routinely given to those with lymph-node or distant metastases; assuming that TRLN lesions could be better controlled by chemotherapy regimens, it could explain that it was PRL and DM tumor burdens that remained the main contributor to the patients’ worse prognosis and ultimately be identified as independent prognostic indicators for PFS and OS. The gene discussed is PRL; the disease is neoplasm.